Relmada Therapeutics, Inc. (RLMD)
Last updated: 2026-10-21 03:05:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Relmada Therapeutics, Inc. (RLMD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.37, with a market capitalization of $330.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.97 to $8.00. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$330.68M | |
$3.17 | |
$54.00 | |
$0.24 | |
$3.16 | |
616.38K | |
1.25M | |
-- | |
$8.00 | |
$1.97 | |
-- | |
-- |
Relmada Therapeutics, Inc. (RLMD) Latest Closing Stock Price
Relmada Therapeutics, Inc. (RLMD) last closed at $3.16 as of 2026-10-20 23:31:00, unchanged from the previous close of $3.16.
During the latest regular trading session, RLMD traded between $0.24 and $54.00, with a volume of 616.38K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Relmada Therapeutics, Inc. (RLMD) 7-Day Stock Price Change
Over the past seven days, Relmada Therapeutics, Inc. (RLMD) moved from $3.39 to $3.37, representing a decline of 0.74% ($0.02).
The stock traded between $3.07 and $3.55 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.27 million shares, down versus the previous seven-day period, indicating lower trading activity.
RLMD 52-Week Price Position
Position in Range: 23.2%
RLMD is currently trading at $3.37, placing it 23.2% of the way from its 52-week low of $1.97 to its 52-week high of $8.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Relmada Therapeutics, Inc. (RLMD)?
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Relmada Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Relmada Therapeutics, Inc. (RLMD) Stock on MEXC
Eligible investors can buy real shares of Relmada Therapeutics, Inc. (RLMD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Relmada Therapeutics, Inc. (RLMD) stock price today?
2.Is RLMD stock going up or down today?
3.What is RLMD pre-market price?
4.What is RLMD after-hours price?
5.Is RLMD stock trading now?
6.Where does RLMD sit relative to its 52-week high and low?
7.What sector is Relmada Therapeutics, Inc. in?
8.What is Relmada Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is RLMD valued in terms of P/E ratio and EPS?
10.Does Relmada Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
RLMD Stock Calculator
Estimate the value between RLMD shares and USD.
RLMD Shares to USD
1.00 RLMD shares = 3.365 USD
Calculations are estimates based on the latest available price and are for reference only.


